Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Anxiolytic Drugs: Benzodiazepines and Buspirone

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...

Anxiolytic Drugs: Overview

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel positive allosteric modulators of alpha 5 subunit-containing GABA<sub>A</sub> receptors (α5-GABA<sub>A</sub>Rs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia.

Schizophrenia research·2026

Same author

Negative allosteric modulation of α5-GABA<sub>A</sub> receptors engages dynamic cortical glutamatergic and GABAergic mechanisms underlying adaptive behavior in mice.

bioRxiv : the preprint server for biology·2026

Same author

A PK/PD study on antihyperalgesia by an α2/3-GABA<sub>A</sub> receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1-GABA<sub>A</sub> receptors.

British journal of pharmacology·2026

Same author

Tetrahydropyrazolopyridinones as a Novel Class of Potent and Highly Selective LIMK Inhibitors.

Journal of medicinal chemistry·2025

Same author

Oxidative Stress-Responsive 1 Kinase Catalytic Activity Promotes Triple Negative Breast Cancer Oncogenic Potential.

ACS pharmacology & translational science·2025

Same author

Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome.

Journal of medicinal chemistry·2024

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics.

¹Department of Neuroscience, Johnson & Johnson Pharmaceutical Research and Development, Building 020, Room 1A6, Turnhoutseweg 30, B-2340, Beerse, Belgium. JAtack1@its.jnj.com

Current Topics in Behavioral Neurosciences

|February 11, 2011

Summary

Selective GABAA receptor modulators offer potential anxiolytic benefits without sedation. However, preclinical data may not always predict human responses, as seen with MRK-409.

More Related Videos

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABA_A Receptors

Published on: November 14, 2014

Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking

Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking

Published on: March 28, 2014

Related Experiment Videos

Last Updated: Jun 4, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABA_A Receptors

Published on: November 14, 2014

Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking

Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking

Published on: March 28, 2014

Area of Science:

Neuroscience
Pharmacology
Psychiatry

Background:

Nonselective benzodiazepines act on GABAA receptors with alpha1, alpha2, alpha3, or alpha5 subunits.
Subtype-selective compounds are being developed for novel pharmacological profiles, aiming for anxiolytic effects without sedation.

Purpose of the Study:

To investigate the anxiolytic and sedative effects of subtype-selective GABAA receptor modulators in humans.
To compare the preclinical profiles of MRK-409, TPA023, and TPA023B with their observed effects in human trials.

Main Methods:

Development and testing of compounds selectively modulating alpha2 and/or alpha3 GABAA receptor subtypes.
Preclinical testing in rodents and primates, followed by human clinical trials for MRK-409, TPA023, and TPA023B.

Main Results:

MRK-409 caused sedation in humans despite preclinical non-sedating anxiolytic effects, attributed to weak alpha1 partial agonism.
TPA023 and TPA023B, lacking alpha1 efficacy, did not cause overt sedation in humans.
TPA023 demonstrated anxiolytic-like effects in Generalized Anxiety Disorder trials and potential cognitive benefits in schizophrenia.

Conclusions:

Compounds selectively modulating GABAA receptor subtypes exhibit distinct pharmacological profiles compared to classical benzodiazepines.
Preclinical data on GABAA receptor modulators may not reliably predict human responses, necessitating careful clinical evaluation.
Further investigation of subtype-selective GABAA modulators is warranted, with a focus on translating preclinical findings to human efficacy and safety.